ACTIVE: not recruiting...Extension Protocol for Virologically Suppressed subjects who completed PRO140_CDO3 study. Started Aug/29/2017...completion Primary date Dec.20/2022...study completion date: April 10th/2023...Assessing long-term safety of LL as a SINGLE-AGENT therapy for the Chronic suppression of CCR5-tropic HIV-1 infection...Quest Clinical Research S.F. Ca.
This should be a slam-dunk...given previous results on safety. Good Find.